Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation
The MRD2STOP trial investigates the cessation of maintenance therapy in multiple myeloma (MM) patients based on achieving measurable residual disease (MRD) negativity. It highlights M-InSight’s clonotypic peptide mass spectrometry (MS) as a groundbreaking technique for monitoring patients off therapy. This method detected trace monoclonal protein (M-protein) in all patients, even those meeting the stringent MRD < 10⁻⁷ threshold, offering unmatched sensitivity compared to traditional techniques. By identifying rising M-protein levels months before clinical progression, M-InSight enables early detection of disease re-emergence, making it an ideal tool for monitoring patients post-therapy.